追加説明:
Ponatinib FC tablets, available in 15 mg, 30 mg and 45 mg strengths, treat leukemia. The pivotal bioequivalence study has passed, with the dossier expected in Q1 2026 and a DCP slot requested for May 2026. Coripharma's generic version is being developed at its R&D facility in Iceland, powered entirely by sustainable energy, with its business development team available to discuss opportunities.
評価とコメントを残す